Angita Pharmaceuticals is dedicated to the discovery of novel targets and drug candidates for addressing unmet needs in diseases of the Central Nervous System (CNS) and CNS-related indications. We in-license novel IP from academia and adopt a flexible licensing model giving the inventor the opportunity to participate in drug discovery projects. Other projects in our discovery pipeline result from in-house research activities and from joint projects with partners. We have access to a cost-effective technology platform of established CROs capable of developing novel pharmaceutical concepts to levels required by industry. In order to ensure focus on our early stage drug discovery projects, development candidates will subsequently be out-licensed.